Merck's TroFuse ADC Shows Breakthrough in Endometrial Cancer Phase 3 Trial

Merck (MRK) announced this week that its pivotal Phase 3 TroFuse-005 trial demonstrated that sacituzumab tirumotecan significantly improved overall survival and progression-free survival compared to chemotherapy in patients with advanced or recurrent endometrial cancer. The trial also met the key secondary endpoint of objective response rate, with no new safety concerns identified. This is the first global Phase 3 study in this setting where an antibody-drug conjugate outperformed chemotherapy on both survival measures.

The Product

Sacituzumab tirumotecan is a Trop-2-directed antibody-drug conjugate (ADC). Trop-2 is a protein overexpressed in many cancers, making it a promising target. The drug delivers a cytotoxic payload directly to cancer cells.

Pricing and Availability

Merck has not yet disclosed pricing details or a timeline for regulatory submission. The company is expected to initiate discussions with regulators based on these results.

Competition

The ADC competes with immunotherapies and hormonal therapies. Its superiority over chemotherapy in a global Phase 3 trial gives it a competitive edge.

Potential Impact on Merck

If approved, the drug could strengthen Merck's oncology pipeline and generate significant revenue. A regulatory filing is anticipated in 2026.